Molecular Glues Competitive Landscape Research Report 2026: Comprehensive Insights About 80+ Companies and 90+ Drugs
Dublin, Feb. 18, 2026 (GLOBE NEWSWIRE) -- The "Molecular Glues - Competitive Landscape, 2026" has been added to ResearchAndMarkets.com's offering.
The "Molecular Glues - Competitive Landscape, 2026" report delivers an extensive analysis of over 80 companies and 90 drugs within the Molecular Glues (MGs) market, encompassing product types, stages, administration routes, and molecule types. The report also highlights inactive pipeline products globally.
Molecular Glues are unique small molecules facilitating protein-protein interactions, significantly impacting previously "undruggable" proteins by exploiting E3 ubiquitin ligases. They hold promise across oncology, neurodegeneration, immunology, and antiviral treatments. Clinically validated examples like thalidomide exemplify their effectiveness, evident in therapies penetrating the blood-brain barrier making them viable for CNS disorders.
MGs demonstrate mechanistic versatility, targeting multiple proteins or entirely new interactions through cooperative binding. This enhances stability, potency, and selectivity, modulating cellular processes such as degradation or stabilization of proteins. Challenges like off-target effects persist, but advances in high-throughput screening, structural biology, and AI-driven modeling are accelerating drug discovery.
The report highlights significant industry milestones:
Key players like Bristol Myers Squibb, Revolution Medicines, and Nurix Therapeutics are prominently featured. Notable products include POMALYST, REVLIMID, and GT919. These developments showcase molecular glues as pivotal in precision medicine, targeting disease-specific proteins and presenting new drug discovery support through collaborations and advances.
In-depth commercial insights include collaborations, agreements, licensing, and acquisition trends. The competitive landscape features comparative assessments based on therapy, development stage, and technology. Critical questions addressed cover the number of companies developing MGs, mid- to late-stage emerging drugs, industry collaborations, and recent technological advancements.
For industry professionals, this report serves as a crucial resource for understanding the evolving landscape of molecular glues, highlighting their transformative potential and the robust pipeline poised to address complex and refractory diseases.
Companies Featured
Key Topics Covered:
Introduction
Executive Summary
Molecular Glues: Overview
Molecular Glues -Analytical Perspective: In-depth Commercial Assessment
Competitive Landscape
Therapeutic Assessment
Molecular Glues: Company and Product Profiles (Marketed Therapies)
Bristol Myers Squibb
POMALYST
Molecular Glues: Company and Product Profiles (Pipeline Therapies)
Late Stage Products (Phase III)
Revolution Medicines, Inc.
Daraxonrasib
Mid Stage Products (Phase II)
Eisai Co Ltd
E 7820
Early Stage Products (Phase I)
Captor Therapeutics
CT-01
Preclinical and Discovery Stage Products
SEED Therapeutics, Inc.
ST-00937
Inactive Products
Molecular Glues- Unmet needs
Molecular Glues - Market drivers and barriers
Appendix
For more information about this report visit https://www.researchandmarkets.com/r/23y12e
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.